• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OrbusNeich launches Combo Plus stent

November 21, 2016 By Sarah Faulkner

OrbusNeich launches Combo stentOrbusNeich said today that it launched the latest version of its dual-therapy stent, the Combo Plus, featuring an antibody biological coating designed to promote vessel healing in patients with complex coronary artery disease.

After the stent is implanted, the biological coating captures endothelial progenitor cells and kicks off formation of an endothelial layer. A coating of bioabsorbable polymer elutes sirolimus to inhibit neointimal hyperplasia, or the growth and movement of vascular smooth muscle cells in the innermost layer of the artery. The accelerated healing process may reduce adverse events and lead to a quicker return of functionality in patients with coronary stenosis, according to the Hong Kong-based company.

The dual therapy stent uses an enhanced balloon catheter, featuring a lower profile design, lubricious coating and reduced shaft diameters.

“Our design improvements provide superior deliverability and powerful performance for complex daily practice,” chairman David Chien said in prepared remarks. “Combo Plus offers physicians a compelling new treatment option for patients with coronary artery disease.”

OrbusNeich 1st launched the Combo dual therapy stent in 2013, touting it as the world’s 1st dual-therapy stent designed to accelerate endothelial coverage while controlling neointimal profileration. The device is supported by a family of clinical studies, totaling more than 6,000 patients across more than 26 countries.

Earlier this year, the company expanded its portfolio to include its Jade and Scoreflex percutaneous transluminal angioplastyballoon devices designed to treat peripheral artery disease. The balloon devices are OrbusNeich’s 1st foray into lower limb and arteriovenous fistula intervention.

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Vascular Tagged With: OrbusNeich

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS